Role of nebulized amphotericin B in the management of allergic bronchopulmonary aspergillosis in cystic fibrosis: Case report and review of literature

References

• Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic fibrosis foundation consensus panel. J Pediatr. 1998;132:589–95.
   PubMed Web of Science ®Google Scholar
• Laufer P, Fink JN, Bruns WT, Unger GF, Kalbfleisch JH, Greenberger PA. Allergic bronchopulmonary aspergillosis in cystic fibrosis. J Allergy Clin Immunol. 1984;73:44–8.
   PubMed Web of Science ®Google Scholar
• Becker JW, Burke W, McDonald G, Greenberger PA, Henderson WR, Aitken ML. Prevalence of allergic bronchopulmonary aspergillosis and atopy in adult patients with cystic fibrosis. Chest. 1996;109:1536–40.
   PubMed Web of Science ®Google Scholar
• Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 2002;110:685–92.
   PubMed Web of Science ®Google Scholar
• Kauffman HF, Beaumont F, Sluiter HJ, de Vries K. Immunologic observations in sera of a patient with allergic bronchopulmonary aspergillosis by means of the enzyme-linked immunosorbent assay. J Allergy Clin Immunol. 1984;74:741–6.
   PubMed Web of Science ®Google Scholar
• Rapaka RR, Kolls JK. Pathogenesis of allergic bronchopulmonary aspergillosis in cystic fibrosis: current understanding and future directions. Med Mycol. 2009;47:S331–7.
   PubMed Web of Science ®Google Scholar
• Agarwal R. What is the current place of azoles in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. Expert Rev Respir Med. 2012;6(4):363–71.
   PubMed Web of Science ®Google Scholar
• Bellmann R. Pharmacodynamics and pharmacokinetics of antifungals for treatment of invasive aspergillosis. Curr Pharm Des. 2013;19(20):3629–47.
   PubMed Web of Science ®Google Scholar
• Bernhard S, Kernland Lang K, Ammann RA, Lüer S, Leibundgut K, Diepold M. Voriconazole-induced phototoxicity in children. Pediatr Infect Dis J. 2012;31(7):769–71.
   PubMed Web of Science ®Google Scholar
• Chu HY, Jain R, Xie H, Pottinger P, Fredricks DN. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events. BMC Infect Dis. 2013;13(1):105.
   PubMed Web of Science ®Google Scholar
• Park WB, Kim NH, Kim KH, Lee SH, Nam WS, Yoon SH. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis. 2012;55(8):1080–7.
   PubMed Web of Science ®Google Scholar
• Hilliard T, Edwards S, Buchdahl R, Francis J, Rosenthal M, Balfour-Lynn I, et al. Voriconazole therapy in children with cystic fibrosis. J Cyst Fibros. 2005;4(4):215–20.
   PubMedGoogle Scholar
• Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs. 2013;73(9):919–34.
   PubMed Web of Science ®Google Scholar
• Proesmans M, Vermeulen F, Vreys M, De Boeck K. Use of nebulized amphotericin B in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. Int J Pediatr. 2010;2010:376287.
   PubMedGoogle Scholar
• Blennow O, Remberger M, Klingspor L, Omazic B, Fransson K, Ljungman P. Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT. Bone Marrow Transplant. 2010;45(12):1710–8.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Iwata S, Iwata H. Allergic bronchopulmonary aspergillosis in a 9-year old boy. Eur J Pediatr. 2002;161:408–9.
   PubMed Web of Science ®Google Scholar
• Sermet-Gaudelus I, Bianchi ML, Garabédian M, Aris RM, Morton A, Hardin DS, et al. European cystic fibrosis bone mineralization guidelines. J Cyst Fibros. 2011;10(Suppl 2):S16–23.
   PubMedGoogle Scholar
• Stevens DA, Schwartz HJ, Lee JY, Moskovitz BL, Jerome DC, Catanzaro A, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med. 2000;342(11):756–62.
   PubMed Web of Science ®Google Scholar
• Knutsen AP, Slavin RG. Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis. Clin Dev Immunol. 2011;2011:843763.
   PubMedGoogle Scholar
• Cochrane Database of Systematic Reviews. Treatments to fight fungal infections which cause allergic bronchopulmonary aspergillosis in people with cystic fibrosis; 2012, issue 6.
   Google Scholar
• Serrano DR, Hernàndez L, Fleire L, Gonzalez-Alvarez I, Montoya A, Ballesteros MP. Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations. Int J Pharm. 2013;447:38–46.
   PubMed Web of Science ®Google Scholar
• Sunakawa K, Tsukimoto I, Tsunematsu Y, Honda M, Iwai N, Maniwa T. Evaluation of the safety and efficacy of liposomal amphotericin B (L-AMB) in children. J Infect Chemother. 2012;18:456–65.
   PubMed Web of Science ®Google Scholar
• Jullien V. Pharmacocinètique et pharmacodynamie des antifongiques en pèdiatrie. Arch Pèdiatr. 2011;18:S42–7.
   PubMedGoogle Scholar
• Burik JA. Role of new antifungal agents in prophylaxis of mycoses in high risk patients. Curr Opin Infect Dis. 2005;18:479–83.
   PubMed Web of Science ®Google Scholar
• Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother. 2002;49(Suppl 1):37–41.
   PubMed Web of Science ®Google Scholar
• Schmitt HJ, Bernard EM, Hauser M, Armstrong D. Aerosol amphotericin B is effective for prophylaxis and therapy in rat model of pulmonary aspergillosis. Antimicrob Agent Chemother. 1988;32:1676–9.
   PubMed Web of Science ®Google Scholar
• Montforte V, Roman A, Gavalda J, Bravo C, Tenorio L, Ferrer A. Nebulized amphotericin B prophylaxis for aspergillus infections in lung transplantation: a study of risk factors. J Heart Lung Transplant. 2001;20:1274–81.
   PubMed Web of Science ®Google Scholar
• Tiddens HA, Pfaff SJ, Van Der Zander T, Ruijgrok EJ. Weekly nebulization of liposomal amphotericin B for the treatment of prednisone dependent ABPA. Pediatr Pulmonol. 2003;36(Suppl 25):301.
   PubMedGoogle Scholar
• Laoudi Y, Paolini JB, Grimfeld A, Just J. Nebulized corticosteroid and amphotericin B: an alternative treatment for ABPA? Eur Respir J. 2008;31:908–9.
   PubMed Web of Science ®Google Scholar
• Hayes D Jr, Murphy BS, Lynch JE, Feola DJ. Aerosolized amphotericin for the treatment of allergic bronchopulmonary aspergillosis. Pediatr Pulmonol. 2010;45(11):1145–8.
   PubMed Web of Science ®Google Scholar
• Van Der Ent CK, Hoekstra H, Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillus with recombinant anti-IgE antibody. Thorax. 2007;62(3):276–7.
   PubMed Web of Science ®Google Scholar
• Tanou K, Zintzaras E, Kaditis AG. Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence. Pediatr Pulmonol. 2014; 49(5):503-7.
   Web of Science ®Google Scholar
• Kuiper L, Ruijgrok EJ. A review on the clinical use of inhaled amphotericin B. J Aerosol Med Pulm Drug Deliv. 2009;22:213–27.
   PubMed Web of Science ®Google Scholar